nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—bile duct cancer	0.843	1	CtDrD
Sorafenib—ABCC2—bile duct—bile duct cancer	0.00425	0.0877	CbGeAlD
Sorafenib—ABCC2—bile—bile duct cancer	0.00327	0.0674	CbGeAlD
Sorafenib—PDGFRA—gall bladder—bile duct cancer	0.00151	0.0311	CbGeAlD
Sorafenib—HIPK3—pancreas—bile duct cancer	0.00123	0.0255	CbGeAlD
Sorafenib—KIT—gall bladder—bile duct cancer	0.0012	0.0249	CbGeAlD
Sorafenib—PDGFRB—gall bladder—bile duct cancer	0.00118	0.0243	CbGeAlD
Sorafenib—CDK7—liver—bile duct cancer	0.000928	0.0192	CbGeAlD
Sorafenib—TAOK2—liver—bile duct cancer	0.000921	0.019	CbGeAlD
Sorafenib—MKNK2—pancreas—bile duct cancer	0.000862	0.0178	CbGeAlD
Sorafenib—ZAK—liver—bile duct cancer	0.000802	0.0166	CbGeAlD
Sorafenib—HIPK3—liver—bile duct cancer	0.000785	0.0162	CbGeAlD
Sorafenib—RALBP1—pancreas—bile duct cancer	0.000779	0.0161	CbGeAlD
Sorafenib—FLT1—pancreas—bile duct cancer	0.000741	0.0153	CbGeAlD
Sorafenib—RAF1—pancreas—bile duct cancer	0.000736	0.0152	CbGeAlD
Sorafenib—TIE1—liver—bile duct cancer	0.000734	0.0151	CbGeAlD
Sorafenib—MAPK11—lymph node—bile duct cancer	0.000723	0.0149	CbGeAlD
Sorafenib—CDK7—lymph node—bile duct cancer	0.000712	0.0147	CbGeAlD
Sorafenib—TAOK2—lymph node—bile duct cancer	0.000706	0.0146	CbGeAlD
Sorafenib—BRAF—liver—bile duct cancer	0.000703	0.0145	CbGeAlD
Sorafenib—AURKC—lymph node—bile duct cancer	0.0007	0.0145	CbGeAlD
Sorafenib—EPHX2—liver—bile duct cancer	0.000672	0.0139	CbGeAlD
Sorafenib—FLT3—liver—bile duct cancer	0.000667	0.0138	CbGeAlD
Sorafenib—ZAK—lymph node—bile duct cancer	0.000615	0.0127	CbGeAlD
Sorafenib—UGT1A9—liver—bile duct cancer	0.000615	0.0127	CbGeAlD
Sorafenib—FLT4—liver—bile duct cancer	0.000606	0.0125	CbGeAlD
Sorafenib—HIPK3—lymph node—bile duct cancer	0.000602	0.0124	CbGeAlD
Sorafenib—FGFR1—liver—bile duct cancer	0.000598	0.0123	CbGeAlD
Sorafenib—MAP3K7—liver—bile duct cancer	0.000566	0.0117	CbGeAlD
Sorafenib—TIE1—lymph node—bile duct cancer	0.000562	0.0116	CbGeAlD
Sorafenib—KIT—pancreas—bile duct cancer	0.000555	0.0115	CbGeAlD
Sorafenib—MKNK2—liver—bile duct cancer	0.000549	0.0113	CbGeAlD
Sorafenib—PDGFRB—pancreas—bile duct cancer	0.000542	0.0112	CbGeAlD
Sorafenib—MKNK1—liver—bile duct cancer	0.000542	0.0112	CbGeAlD
Sorafenib—BRAF—lymph node—bile duct cancer	0.000539	0.0111	CbGeAlD
Sorafenib—EPHX2—lymph node—bile duct cancer	0.000515	0.0106	CbGeAlD
Sorafenib—FLT3—lymph node—bile duct cancer	0.000512	0.0106	CbGeAlD
Sorafenib—CYP3A7—liver—bile duct cancer	0.000511	0.0106	CbGeAlD
Sorafenib—RALBP1—liver—bile duct cancer	0.000496	0.0102	CbGeAlD
Sorafenib—FLT1—liver—bile duct cancer	0.000471	0.00973	CbGeAlD
Sorafenib—RAF1—liver—bile duct cancer	0.000469	0.00967	CbGeAlD
Sorafenib—FLT4—lymph node—bile duct cancer	0.000465	0.00959	CbGeAlD
Sorafenib—FGFR1—lymph node—bile duct cancer	0.000458	0.00946	CbGeAlD
Sorafenib—STK10—liver—bile duct cancer	0.000446	0.00921	CbGeAlD
Sorafenib—PDGFRA—liver—bile duct cancer	0.000442	0.00912	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—bile duct cancer	0.000435	0.00897	CbGeAlD
Sorafenib—MAP3K7—lymph node—bile duct cancer	0.000434	0.00896	CbGeAlD
Sorafenib—ABCC4—pancreas—bile duct cancer	0.000432	0.00891	CbGeAlD
Sorafenib—UGT1A1—liver—bile duct cancer	0.000421	0.0087	CbGeAlD
Sorafenib—MKNK2—lymph node—bile duct cancer	0.000421	0.00868	CbGeAlD
Sorafenib—MKNK1—lymph node—bile duct cancer	0.000415	0.00857	CbGeAlD
Sorafenib—RET—lymph node—bile duct cancer	0.00041	0.00847	CbGeAlD
Sorafenib—MAP2K5—liver—bile duct cancer	0.000398	0.00822	CbGeAlD
Sorafenib—KDR—liver—bile duct cancer	0.000398	0.00822	CbGeAlD
Sorafenib—CSF1R—liver—bile duct cancer	0.000389	0.00803	CbGeAlD
Sorafenib—RALBP1—lymph node—bile duct cancer	0.00038	0.00784	CbGeAlD
Sorafenib—FLT1—lymph node—bile duct cancer	0.000361	0.00746	CbGeAlD
Sorafenib—RAF1—lymph node—bile duct cancer	0.000359	0.00742	CbGeAlD
Sorafenib—EPHB6—lymph node—bile duct cancer	0.000357	0.00737	CbGeAlD
Sorafenib—KIT—liver—bile duct cancer	0.000353	0.00729	CbGeAlD
Sorafenib—PDGFRB—liver—bile duct cancer	0.000345	0.00712	CbGeAlD
Sorafenib—STK10—lymph node—bile duct cancer	0.000342	0.00706	CbGeAlD
Sorafenib—PDGFRA—lymph node—bile duct cancer	0.000339	0.00699	CbGeAlD
Sorafenib—KDR—lymph node—bile duct cancer	0.000305	0.00631	CbGeAlD
Sorafenib—MAP2K5—lymph node—bile duct cancer	0.000305	0.00631	CbGeAlD
Sorafenib—CSF1R—lymph node—bile duct cancer	0.000298	0.00615	CbGeAlD
Sorafenib—CYP3A5—pancreas—bile duct cancer	0.000283	0.00584	CbGeAlD
Sorafenib—ABCC4—liver—bile duct cancer	0.000275	0.00567	CbGeAlD
Sorafenib—KIT—lymph node—bile duct cancer	0.000271	0.00559	CbGeAlD
Sorafenib—ABCC2—liver—bile duct cancer	0.000266	0.00549	CbGeAlD
Sorafenib—PDGFRB—lymph node—bile duct cancer	0.000264	0.00546	CbGeAlD
Sorafenib—CYP2C19—liver—bile duct cancer	0.000228	0.00471	CbGeAlD
Sorafenib—ABCC4—lymph node—bile duct cancer	0.000211	0.00435	CbGeAlD
Sorafenib—HTR2B—lymph node—bile duct cancer	0.000209	0.00432	CbGeAlD
Sorafenib—ABCC2—lymph node—bile duct cancer	0.000204	0.00421	CbGeAlD
Sorafenib—CYP2C8—liver—bile duct cancer	0.000199	0.00411	CbGeAlD
Sorafenib—ABCG2—liver—bile duct cancer	0.000194	0.004	CbGeAlD
Sorafenib—CYP1A2—liver—bile duct cancer	0.000187	0.00385	CbGeAlD
Sorafenib—CYP3A5—liver—bile duct cancer	0.00018	0.00371	CbGeAlD
Sorafenib—CYP2B6—liver—bile duct cancer	0.000179	0.00369	CbGeAlD
Sorafenib—CYP2C9—liver—bile duct cancer	0.000177	0.00366	CbGeAlD
Sorafenib—ABCB1—pancreas—bile duct cancer	0.00015	0.0031	CbGeAlD
Sorafenib—ABCG2—lymph node—bile duct cancer	0.000149	0.00307	CbGeAlD
Sorafenib—CYP3A4—liver—bile duct cancer	0.000135	0.00279	CbGeAlD
Sorafenib—CYP2D6—liver—bile duct cancer	0.000133	0.00274	CbGeAlD
Sorafenib—ABCB1—liver—bile duct cancer	9.56e-05	0.00197	CbGeAlD
Sorafenib—ABCB1—lymph node—bile duct cancer	7.33e-05	0.00151	CbGeAlD
Sorafenib—MKNK1—Signaling Pathways—TP53—bile duct cancer	6.49e-06	6e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—HRAS—bile duct cancer	6.47e-06	5.97e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFBR2—bile duct cancer	6.42e-06	5.93e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—ERBB2—bile duct cancer	6.31e-06	5.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—bile duct cancer	6.31e-06	5.83e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—IDH1—bile duct cancer	6.3e-06	5.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HRAS—bile duct cancer	6.27e-06	5.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—bile duct cancer	6.25e-06	5.78e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—bile duct cancer	6.25e-06	5.77e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—bile duct cancer	6.21e-06	5.74e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—GNAS—bile duct cancer	6.19e-06	5.72e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—NRAS—bile duct cancer	6.19e-06	5.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—bile duct cancer	6.17e-06	5.7e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EGFR—bile duct cancer	6.16e-06	5.69e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NRAS—bile duct cancer	6.1e-06	5.63e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—NRAS—bile duct cancer	6.1e-06	5.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—ERBB2—bile duct cancer	6.09e-06	5.63e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SMAD4—bile duct cancer	6.08e-06	5.61e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—bile duct cancer	5.98e-06	5.52e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC5A5—bile duct cancer	5.98e-06	5.52e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—bile duct cancer	5.94e-06	5.49e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MMP9—bile duct cancer	5.88e-06	5.43e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—bile duct cancer	5.85e-06	5.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—bile duct cancer	5.82e-06	5.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KRAS—bile duct cancer	5.82e-06	5.38e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NRAS—bile duct cancer	5.79e-06	5.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NRAS—bile duct cancer	5.77e-06	5.33e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—bile duct cancer	5.75e-06	5.31e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ERBB2—bile duct cancer	5.75e-06	5.31e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MMP9—bile duct cancer	5.73e-06	5.3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ERBB2—bile duct cancer	5.69e-06	5.26e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—IDH2—bile duct cancer	5.65e-06	5.22e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—bile duct cancer	5.64e-06	5.21e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—bile duct cancer	5.63e-06	5.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—ERBB2—bile duct cancer	5.63e-06	5.2e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	5.6e-06	5.17e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—bile duct cancer	5.59e-06	5.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—bile duct cancer	5.59e-06	5.16e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—bile duct cancer	5.57e-06	5.15e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—bile duct cancer	5.56e-06	5.13e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—bile duct cancer	5.56e-06	5.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—bile duct cancer	5.5e-06	5.08e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GNAS—bile duct cancer	5.49e-06	5.07e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—bile duct cancer	5.43e-06	5.01e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GNAS—bile duct cancer	5.36e-06	4.95e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—bile duct cancer	5.35e-06	4.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—bile duct cancer	5.34e-06	4.94e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC5A5—bile duct cancer	5.33e-06	4.93e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—bile duct cancer	5.33e-06	4.92e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—KRAS—bile duct cancer	5.32e-06	4.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—bile duct cancer	5.27e-06	4.87e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—bile duct cancer	5.26e-06	4.86e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—KRAS—bile duct cancer	5.25e-06	4.85e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KRAS—bile duct cancer	5.25e-06	4.85e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—bile duct cancer	5.23e-06	4.83e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—bile duct cancer	5.22e-06	4.82e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC5A5—bile duct cancer	5.21e-06	4.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—bile duct cancer	5.2e-06	4.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ERBB2—bile duct cancer	5.18e-06	4.79e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ERBB2—bile duct cancer	5.18e-06	4.79e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—bile duct cancer	5.13e-06	4.74e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—bile duct cancer	5.09e-06	4.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—bile duct cancer	5.07e-06	4.69e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	5e-06	4.62e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KRAS—bile duct cancer	4.98e-06	4.6e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KRAS—bile duct cancer	4.97e-06	4.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—bile duct cancer	4.97e-06	4.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—bile duct cancer	4.95e-06	4.57e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—bile duct cancer	4.95e-06	4.57e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—bile duct cancer	4.95e-06	4.57e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—bile duct cancer	4.93e-06	4.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ERBB2—bile duct cancer	4.92e-06	4.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ERBB2—bile duct cancer	4.91e-06	4.53e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC5A5—bile duct cancer	4.91e-06	4.53e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—bile duct cancer	4.88e-06	4.51e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—bile duct cancer	4.87e-06	4.5e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC5A5—bile duct cancer	4.86e-06	4.49e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—IDH1—bile duct cancer	4.86e-06	4.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—bile duct cancer	4.86e-06	4.49e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—bile duct cancer	4.85e-06	4.48e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—KRAS—bile duct cancer	4.85e-06	4.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—bile duct cancer	4.8e-06	4.44e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—bile duct cancer	4.75e-06	4.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—bile duct cancer	4.74e-06	4.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—bile duct cancer	4.74e-06	4.37e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—bile duct cancer	4.74e-06	4.37e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—bile duct cancer	4.74e-06	4.37e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—bile duct cancer	4.73e-06	4.36e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—KRAS—bile duct cancer	4.67e-06	4.32e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNAS—bile duct cancer	4.64e-06	4.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—bile duct cancer	4.64e-06	4.28e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—bile duct cancer	4.63e-06	4.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—bile duct cancer	4.62e-06	4.27e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KRAS—bile duct cancer	4.6e-06	4.25e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KRAS—bile duct cancer	4.59e-06	4.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	4.56e-06	4.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—bile duct cancer	4.53e-06	4.18e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—bile duct cancer	4.49e-06	4.15e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—bile duct cancer	4.48e-06	4.13e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—bile duct cancer	4.46e-06	4.12e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—bile duct cancer	4.46e-06	4.12e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—bile duct cancer	4.46e-06	4.12e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—bile duct cancer	4.45e-06	4.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—bile duct cancer	4.45e-06	4.11e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—bile duct cancer	4.42e-06	4.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—bile duct cancer	4.38e-06	4.05e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—bile duct cancer	4.38e-06	4.04e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—bile duct cancer	4.38e-06	4.04e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—bile duct cancer	4.37e-06	4.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—bile duct cancer	4.37e-06	4.03e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—bile duct cancer	4.33e-06	4e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—bile duct cancer	4.33e-06	4e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—bile duct cancer	4.28e-06	3.95e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—bile duct cancer	4.27e-06	3.94e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—bile duct cancer	4.27e-06	3.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—bile duct cancer	4.23e-06	3.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—bile duct cancer	4.22e-06	3.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—bile duct cancer	4.22e-06	3.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—bile duct cancer	4.22e-06	3.9e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—bile duct cancer	4.22e-06	3.89e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—bile duct cancer	4.21e-06	3.89e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC5A5—bile duct cancer	4.16e-06	3.84e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNAS—bile duct cancer	4.14e-06	3.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—bile duct cancer	4.13e-06	3.82e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—bile duct cancer	4.12e-06	3.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—bile duct cancer	4.06e-06	3.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—bile duct cancer	4.05e-06	3.74e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNAS—bile duct cancer	4.05e-06	3.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—bile duct cancer	4.04e-06	3.73e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—bile duct cancer	4.03e-06	3.72e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—bile duct cancer	4.02e-06	3.71e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—bile duct cancer	3.99e-06	3.69e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—bile duct cancer	3.99e-06	3.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—bile duct cancer	3.99e-06	3.69e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—bile duct cancer	3.98e-06	3.68e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—bile duct cancer	3.98e-06	3.68e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—bile duct cancer	3.98e-06	3.67e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—bile duct cancer	3.97e-06	3.67e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—bile duct cancer	3.95e-06	3.65e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—bile duct cancer	3.94e-06	3.64e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—bile duct cancer	3.94e-06	3.64e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—bile duct cancer	3.94e-06	3.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—bile duct cancer	3.94e-06	3.64e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—bile duct cancer	3.91e-06	3.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—bile duct cancer	3.9e-06	3.6e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—bile duct cancer	3.9e-06	3.6e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	3.89e-06	3.6e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—bile duct cancer	3.89e-06	3.59e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—bile duct cancer	3.82e-06	3.53e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNAS—bile duct cancer	3.81e-06	3.52e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—bile duct cancer	3.81e-06	3.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—bile duct cancer	3.8e-06	3.51e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—bile duct cancer	3.79e-06	3.5e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNAS—bile duct cancer	3.78e-06	3.49e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—bile duct cancer	3.77e-06	3.48e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—bile duct cancer	3.76e-06	3.48e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—bile duct cancer	3.74e-06	3.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—bile duct cancer	3.74e-06	3.46e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—bile duct cancer	3.73e-06	3.45e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—bile duct cancer	3.73e-06	3.45e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—bile duct cancer	3.73e-06	3.44e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—bile duct cancer	3.72e-06	3.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—bile duct cancer	3.71e-06	3.43e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—bile duct cancer	3.68e-06	3.4e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—bile duct cancer	3.66e-06	3.38e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—bile duct cancer	3.66e-06	3.38e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—bile duct cancer	3.65e-06	3.37e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—bile duct cancer	3.64e-06	3.36e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—bile duct cancer	3.62e-06	3.34e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—bile duct cancer	3.59e-06	3.32e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—bile duct cancer	3.59e-06	3.32e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—bile duct cancer	3.56e-06	3.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—bile duct cancer	3.55e-06	3.28e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—bile duct cancer	3.51e-06	3.24e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—bile duct cancer	3.48e-06	3.21e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—bile duct cancer	3.47e-06	3.2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—bile duct cancer	3.41e-06	3.15e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—bile duct cancer	3.4e-06	3.14e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—bile duct cancer	3.4e-06	3.14e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—bile duct cancer	3.39e-06	3.13e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—bile duct cancer	3.39e-06	3.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—bile duct cancer	3.39e-06	3.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—bile duct cancer	3.38e-06	3.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—bile duct cancer	3.36e-06	3.11e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—bile duct cancer	3.36e-06	3.11e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—bile duct cancer	3.35e-06	3.09e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—bile duct cancer	3.31e-06	3.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—bile duct cancer	3.25e-06	3e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNAS—bile duct cancer	3.23e-06	2.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—bile duct cancer	3.22e-06	2.97e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—bile duct cancer	3.21e-06	2.97e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	3.21e-06	2.96e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—bile duct cancer	3.21e-06	2.96e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—bile duct cancer	3.2e-06	2.96e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—bile duct cancer	3.2e-06	2.95e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—bile duct cancer	3.17e-06	2.93e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—bile duct cancer	3.13e-06	2.89e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—bile duct cancer	3.12e-06	2.89e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—bile duct cancer	3.07e-06	2.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—bile duct cancer	3.06e-06	2.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—bile duct cancer	3.06e-06	2.83e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—bile duct cancer	3.03e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—bile duct cancer	3.02e-06	2.79e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—bile duct cancer	3.02e-06	2.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—bile duct cancer	3e-06	2.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—bile duct cancer	3e-06	2.77e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—bile duct cancer	2.98e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—bile duct cancer	2.95e-06	2.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—bile duct cancer	2.92e-06	2.7e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—bile duct cancer	2.92e-06	2.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—bile duct cancer	2.89e-06	2.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—bile duct cancer	2.88e-06	2.66e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—bile duct cancer	2.88e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—bile duct cancer	2.88e-06	2.66e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—bile duct cancer	2.86e-06	2.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—bile duct cancer	2.86e-06	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—bile duct cancer	2.79e-06	2.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—bile duct cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—bile duct cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—bile duct cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—bile duct cancer	2.74e-06	2.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—bile duct cancer	2.73e-06	2.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—bile duct cancer	2.73e-06	2.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—bile duct cancer	2.62e-06	2.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—bile duct cancer	2.61e-06	2.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—bile duct cancer	2.59e-06	2.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—bile duct cancer	2.58e-06	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—bile duct cancer	2.57e-06	2.38e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—bile duct cancer	2.49e-06	2.3e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAS—bile duct cancer	2.49e-06	2.3e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—bile duct cancer	2.46e-06	2.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—bile duct cancer	2.45e-06	2.27e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—bile duct cancer	2.4e-06	2.22e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—bile duct cancer	2.36e-06	2.18e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—bile duct cancer	2.35e-06	2.17e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—bile duct cancer	2.35e-06	2.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—bile duct cancer	2.29e-06	2.12e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—bile duct cancer	2.25e-06	2.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—bile duct cancer	2.23e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—bile duct cancer	2.23e-06	2.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—bile duct cancer	2.19e-06	2.03e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—bile duct cancer	2.17e-06	2.01e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—bile duct cancer	2.1e-06	1.94e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—bile duct cancer	2.05e-06	1.89e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—bile duct cancer	2.03e-06	1.87e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—bile duct cancer	1.98e-06	1.83e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—bile duct cancer	1.89e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—bile duct cancer	1.81e-06	1.67e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—bile duct cancer	1.73e-06	1.6e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—bile duct cancer	1.34e-06	1.24e-05	CbGpPWpGaD
